Literature DB >> 31685419

The Pathophysiology of Myocardial Ischemia and Perioperative Myocardial Infarction.

Marli Smit1, A R Coetzee2, A Lochner3.   

Abstract

Ischemic heart disease, the leading cause of death worldwide, may result in devastating perioperative ischemia and infarction. The underlying pathophysiology, precipitating factors, and approach to prevention differ between patients presenting for noncardiac surgery, developing acute coronary syndrome versus stable angina. The first half of this article reviews the pathophysiology of acute coronary syndrome and stable angina. Acute coronary syndrome, otherwise known as Type 1 myocardial infarction, includes unstable angina, non-ST segment elevated myocardial infarction and ST segment elevated myocardial infarction. Acute coronary syndrome occurs as a result of vulnerable plaque rupture with subsequent varying degrees of thrombus formation, arterial spasm, and thus coronary occlusion. Stable angina, on the other hand, results from a myocardial oxygen delivery and demand mismatch in the setting of fixed coronary stenosis. After this discussion, the review article considers how both apply to perioperative myocardial infarctions and myocardial injury after noncardiac surgery. This article furthermore argues why myocardial oxygen delivery demand mismatch (Type 2) myocardial infarction is the most likely underlying pathophysiology responsible for perioperative myocardial infarctions. Being aware of this and knowledgeable about Type 2 infarctions may enable anesthetic providers to better predict the majority of triggers contributing to, and thus decreasing the incidence of, perioperative myocardial infarctions.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  acute coronary syndrome; myocardial injury after non cardiac surgery; pathophysiology; peri-operative myocardial infarction; stable angina

Mesh:

Year:  2019        PMID: 31685419     DOI: 10.1053/j.jvca.2019.10.005

Source DB:  PubMed          Journal:  J Cardiothorac Vasc Anesth        ISSN: 1053-0770            Impact factor:   2.628


  14 in total

1.  Specific protein 1 inhibitor mithramycin A protects cardiomyocytes from myocardial infarction via interacting with PARP.

Authors:  Haihua Geng; Yamin Su; Rong Huang; Mengkang Fan; Xiaofei Li; Xiaochen Lu; Hongzhuan Sheng
Journal:  In Vitro Cell Dev Biol Anim       Date:  2021-02-12       Impact factor: 2.416

Review 2.  Polymeric nanoparticles in the diagnosis and treatment of myocardial infarction: Challenges and future prospects.

Authors:  Mia Karam; Duaa Fahs; Batoul Maatouk; Brouna Safi; Ayad A Jaffa; Rami Mhanna
Journal:  Mater Today Bio       Date:  2022-04-04

3.  An "occlusive thrombosis-on-a-chip" microfluidic device for investigating the effect of anti-thrombotic drugs.

Authors:  Jess Berry; François J Peaudecerf; Nicole A Masters; Keith B Neeves; Raymond E Goldstein; Matthew T Harper
Journal:  Lab Chip       Date:  2021-10-26       Impact factor: 7.517

4.  Colchicine effectively attenuates inflammatory biomarker high-sensitivity C-reactive protein (hs-CRP) in patients with non-ST-segment elevation myocardial infarction: a randomised, double-blind, placebo-controlled clinical trial.

Authors:  Arash Gholoobi; Vahid Reza Askari; Hossein Naghedinia; Mostafa Ahmadi; Vida Vakili; Vafa Baradaran Rahimi
Journal:  Inflammopharmacology       Date:  2021-08-21       Impact factor: 4.473

5.  Myocardial repair of bioengineered cardiac patches with decellularized placental scaffold and human-induced pluripotent stem cells in a rat model of myocardial infarction.

Authors:  Yu Jiang; Si-Jia Sun; Zhe Zhen; Rui Wei; Nannan Zhang; Song-Yan Liao; Hung-Fat Tse
Journal:  Stem Cell Res Ther       Date:  2021-01-07       Impact factor: 6.832

6.  Necroptosis Inhibition by Hydrogen Sulfide Alleviated Hypoxia-Induced Cardiac Fibroblasts Proliferation via Sirtuin 3.

Authors:  Yue Zhang; Weiwei Gong; Mengting Xu; Shuping Zhang; Jieru Shen; Mingxian Zhu; Yuqin Wang; Yun Chen; Jiahai Shi; Guoliang Meng
Journal:  Int J Mol Sci       Date:  2021-11-02       Impact factor: 5.923

Review 7.  Pathophysiology of stress granules: An emerging link to diseases (Review).

Authors:  Jihui Wang; Yixia Gan; Jian Cao; Xuefen Dong; Wei Ouyang
Journal:  Int J Mol Med       Date:  2022-02-09       Impact factor: 4.101

8.  Putative Prevention of XML Injection Against Myocardial Ischemia Is Mediated by PKC and PLA2 Proteins.

Authors:  Ling Jin; Qianqian Yin; Yiqing Mao; Yuanxu Gao; Qing Han; Ruisi Mei; Lixiang Xue; Huanran Tan; Hui Li
Journal:  Front Cell Dev Biol       Date:  2022-01-24

Review 9.  Long non-coding RNA OIP5-AS1 (Cyrano): A context-specific regulator of normal and disease processes.

Authors:  Serena Wooten; Keriayn N Smith
Journal:  Clin Transl Med       Date:  2022-01

10.  The Composite of 3, 4-Dihydroxyl-Phenyl Lactic Acid and Notoginsenoside R1 Attenuates Myocardial Ischemia and Reperfusion Injury Through Regulating Mitochondrial Respiratory Chain.

Authors:  Li Yan; Chun-Shui Pan; Yu-Ying Liu; Yuan-Chen Cui; Bai-He Hu; Xin Chang; Xiao-Hong Wei; Ping Huang; Jian Liu; Jing-Yu Fan; Quan Li; Kai Sun; Lu-Lu Yan; Ke He; Jing-Yan Han
Journal:  Front Physiol       Date:  2021-07-12       Impact factor: 4.566

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.